February 1, 2013
GlaxoSmithKline is running a placebo controlled study to examine the benefit to late stage melanoma patients of combined therapies. They are testing “BRAF blocker dabrafenib and MEK inhibitor trametinib in patients whose BRAF V600E mutation-positive melanoma has been surgically removed.”
Some patients on these drugs, dabrafenib and trametinib, have developed another skin cancer, cutaneous squamous cell carcinoma.
…patients on the combo lived 9.4 months without their cancer worsening compared with 5.8 months in the dabrafenib-only group.